Tag: Aristada

Nonadherence to daily oral antipsychotics is a leading cause of relapse and rehospitalization for individuals with schizophrenia. To address this critical issue, the long-acting injectable (LAI) medication Aristada offers significant benefits by providing a less frequent, more convenient treatment option.

Aristada (aripiprazole lauroxil) is a long-acting injectable suspension indicated for the treatment of schizophrenia, offering different dosing frequencies to support patient adherence. The administration of this medication requires specific training and must be performed by a healthcare professional, making it crucial to understand the proper procedure for how to administer an Aristada injection safely and effectively.